GeoVax Labs, a clinical-stage biotechnology company, has appointed Dr. Senthil Ranganathan as Vice President of Technical Development and CMC Operations, a strategic hire that underscores the company's commitment to advancing its vaccine and immunotherapy development pipeline.
With over 20 years of experience in biologics development, Dr. Ranganathan brings extensive expertise in transforming scientific research into commercial-ready products. His background spans vaccines, cell and gene therapies, monoclonal antibodies, and viral vector products, positioning him to support GeoVax's diverse portfolio of infectious disease and cancer therapies.
The appointment comes at a critical juncture for GeoVax, which is developing multiple promising clinical programs. These include a next-generation COVID-19 vaccine targeting immunocompromised patients, a gene-directed therapy for solid tumors, and a vaccine addressing Mpox and smallpox.
Prior to joining GeoVax, Dr. Ranganathan held senior leadership roles at prominent biopharmaceutical companies, including National Resilience, Athersys, Zymeworks, and Alder Biopharmaceuticals. His expertise in navigating complex regulatory landscapes and bringing innovative therapies from pre-investigational new drug (IND) stages through licensure will be crucial for the company's growth.
David Dodd, GeoVax's Chairman and CEO, emphasized the strategic importance of this hire, noting Dr. Ranganathan's potential to support the company's progress toward authorization and commercialization of its development portfolio.
The addition of Dr. Ranganathan signals GeoVax's strategic focus on developing cutting-edge medical solutions that address significant unmet medical needs, contribute to biodefense readiness, and potentially improve vaccine and therapeutic accessibility.
